Management ChangeJul 14, 2026, 08:01 AM
Humacyte Appoints Dr. Kossmann & Dr. Roy-Chaudhury as Advisors
AI Summary
Humacyte, Inc. announced the appointment of Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors. These leading nephrologists will assist in preparing for the planned commercialization of the acellular tissue engineered vessel (ATEV) for hemodialysis access. Their roles will involve developing health economic, reimbursement, and market access strategies, as well as providing scientific and medical education support. This strategic move follows the recent release of positive Phase 3 study results and Humacyte's intention to file a supplemental Biologic License Application with the FDA.
Key Highlights
- Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury appointed as advisors.
- Advisors will prepare for Humacyte's ATEV commercialization in hemodialysis access.
- They will contribute to health economic, reimbursement, and market access strategies.
- They will also provide peer-to-peer scientific support and medical education.
- Appointments follow positive V012 Phase 3 dialysis access study results.
- Humacyte plans to file a supplemental Biologic License Application (sBLA).
- Dr. Kossmann previously served as EVP and CMO for Fresenius Medical Care North America.
- Dr. Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology.
Price Impact
More from HUMA